IQVIA Holdings Inc. $IQV Shares Bought by Punch & Associates Investment Management Inc.

Key Points

• Punch & Associates Investment Management Inc. increased its stake in IQVIA Holdings Inc. by 16.6% during the first quarter, now owning 68,765 shares valued at approximately $12.12 million.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, beating estimates, with a revenue of $4.02 billion, up 5.3% year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for IQVIA, with an average price target of $229.86 per share.

Punch & Associates Investment Management Inc. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 16.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 68,765 shares of the medical research company's stock after purchasing an additional 9,791 shares during the quarter. Punch & Associates Investment Management Inc.'s holdings in IQVIA were worth $12,123,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. American National Bank & Trust acquired a new stake in shares of IQVIA during the first quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the 1st quarter worth $33,000. Finally, ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $187.75 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $249.43. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $31.92 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 2.02 and a beta of 1.32. The stock's 50-day simple moving average is $179.88 and its 200 day simple moving average is $167.61.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Robert W. Baird upped their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Mizuho lifted their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research note on Wednesday. Finally, Evercore ISI raised their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $229.86.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.